Osteoprotegerin gene polymorphism in diabetic Charcot neuroarthropathy

Abstract

We suggest that genetic factors, particularly OPG gene polymorphisms, may play a role in the development of diabetic Charcot neuroarthropathy.

Prevalence of polymorphisms in OPG, RANKL and RANK as potential markers for Charcot arthropathy development

“…Consistently with previous reports, the strongest association with CN was observed for the OPG 1181G/C polymorphism 17, 18 . Moreover, although the hierarchical clustering did not show any characteristic OPG 1181G/C genotype pattern for a particular patient cluster, the majority of patients with the CC genotype belongs to the CN and N groups (Fig.…”

“…To date, studies addressing a possible link between genotype and Charcot arthropathy have been limited to the analysis of the OPG gene polymorphisms 17, 18 . In the study presented here, we have analysed additional SNPs that have been associated with altered bone metabolism in postmenopausal women 20, 21 .…”

“…In contrast to previous studies 17, 18 , we aimed to find differences between CN, N and the D group, which was used as the control group. This distinction allowed for finding that OPG 6890A/C is associated with both, CN and N. However, as in the case of OPG 1217C/T, this SNP is located in the intron sequence and it is unclear how this position contributes to the development of CN and N. Furthermore, OPG 6890A/C was clustered together with OPG 1217C/T, OPG 245T/G and RANK 421C/T polymorphisms, which did not show distribution patterns (Fig.…”

Treatment of acute Charcot foot with bisphosphonates: a systematic review of the literature

“…Moreover, recent studies have emphasised the involvement of the RANK-L/ RANK/OPG axis as certain genetic variants of the OPG (also known as TNFRSF11B) polymorphism may predispose diabetic patients to CNO. According to this hypothesis, it would be conceivable that variations in some regions of OPG could result in quantitative and/or qualitative alterations of OPG, decreasing the buffering role of OPG against RANK-L [26,27]. The cornerstone of CNO management is immobilisation and off-loading, which aims to prevent severe deformity, ulceration and, ultimately, amputation [3,6,9,28].…”

Classifications in Brief: Eichenholtz Classification of Charcot Arthropathy

“…The literature pertaining to Charcot arthropathy has acknowledged this lack of validation, citing the subjectivity of the classification's stages and the difficulties encountered when attempting to distinguish the end of one stage and the beginning of the next as impediments to proper validation [6]. There are other challenges that complicate validation, including the limited prevalence of Charcot arthropathy, which is reported to be 0.08% to 7.5% in patients with diabetes, the high frequency of delayed and missed diagnoses, and the multitude of joints affected [14,15]. Additionally, validation requires assessment of each patient's imaging and physical examination findings by multiple observers at one time, and with time, which can be difficult to facilitate.…”